Application of apigenin in preparation of products for preventing and treating alopecia

Abstract

The invention discloses an application of apigenin in preparation of a product for preventing and treating alopecia, and relates to the technical field of alopecia prevention and treatment, and the key point of the technical scheme is that the apigenin can play a role in regulating the hair follicle cycle in the hair follicle growth and development process, specifically, the apigenin activates hair follicle stem cell proliferation, promotes the hair follicle to change from a resting stage to a growing stage, and promotes the hair follicle growth. The apigenin can promote hair growth, can theoretically treat alopecia diseases such as androgenetic alopecia, alopecia areata and alopecia in a growing period caused by human hair growth cycle stagnation, and has the advantages of wide source of apigenin, low cost and high biological safety.

Description

Technical Field

[0001] The present invention relates to the technical field of preventing and treating hair loss, and more particularly to application of apigenin in preparing products for preventing and treating hair loss. Background Art

[0002] As people's living standards improve, their expectations for hair care products are also increasing. However, the accelerated pace of life, increased work pressure, and deteriorating living environments are leading to an increasing number of people experiencing hair breakage, hair loss, and thinning, with more and more people experiencing fine, wispy hair. Existing anti-hair loss products primarily contain chemicals that degrease and stimulate hair follicles. While these products may cleanse the scalp and stimulate hair growth in the short term, long-term use can have the opposite effect. Some shampoos based purely on traditional Chinese herbal remedies are not very effective in preventing hair loss and promoting hair growth.

[0003] Apigenin (APG) is a flavonoid compound that is widely found in aromatic plants (such as chamomile, mint, parsley), honey and wheat. Studies have shown that apigenin has anti-inflammatory, antioxidant, free radical scavenging and anti-cancer activities, and also exhibits significant estrogen-like effects. At present, although commonly used hair growth-promoting products on the market, such as minoxidil and finasteride, have certain clinical effects, they still have limitations: limited efficacy, long-term use is required, not suitable for all people, and may be accompanied by side effects and high costs. In contrast, apigenin, as a natural plant extract, not only has good hair growth-promoting potential, but also has the advantages of high safety, low side effects, low cost and strong universality due to its widespread presence in daily food. It is a very promising natural hair growth ingredient. In view of this, the inventors propose the use of apigenin in the preparation of products for preventing and treating hair loss. Summary of the Invention

[0004] The purpose of the present invention is to provide the use of apigenin in preparing a product for preventing and treating hair loss.

[0005] The above technical purpose of the present invention is achieved through the following technical solution: application of apigenin in the preparation of products for preventing and treating hair loss.

[0006] The present invention is further configured as follows: the hair loss is a hair loss disease caused by stagnation of the hair growth cycle.

[0007] The present invention is further configured as follows: the hair loss diseases caused by the stagnation of the hair growth cycle include androgenic alopecia, alopecia areata, and anagen effluvium.

[0008] The present invention is further configured as follows: the product is a medicine or health product that activates the proliferation of hair follicle stem cells, promotes the transition of hair follicles from the resting phase to the growth phase, and promotes hair growth.

[0009] The present invention is further configured such that the medicine is in the form of tablets, capsules, pills or oral liquids.

[0010] In summary, the present invention has the following beneficial effects:

[0011] 1. Apigenin can regulate the hair follicle cycle during the growth and development of hair follicles. Specifically, it activates the proliferation of hair follicle stem cells, promotes the transition of hair follicles from the resting phase to the growth phase, and promotes hair growth. In theory, it can treat hair loss diseases caused by the stagnation of the human hair growth cycle, such as androgenic alopecia, alopecia areata, and growth effluvium.

[0012] 2. Apigenin is widely available, low cost and highly biosafe. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 This is a schematic diagram of the mouse hair cycle in Example 1 of the present invention;

[0014] Figure 2 HE staining images at D10 (from telogen to anagen); HE staining images at D24 (from anagen to catagen); and HE staining images at D29 (from catagen to telogen) in Example 1 of the present invention.

[0015] Figure 3 This is a statistical graph of hair length on D19 and D24 in Example 1 of the present invention (Note: hair of mice was collected on D19 and D24 and hair length was randomly measured);

[0016] Figure 4 Lineage tracing of lgr5+ hair follicle stem cells in mice at D5 and D8 in Example 2 of the present invention. DETAILED DESCRIPTION

[0017] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0018] Experimental animals:

[0019] Twenty-four healthy mice aged seven weeks, weighing 20±1 g, were selected as experimental animals. They were housed in an experimental animal room according to the standard feeding conditions, with a 12-h light cycle, an indoor temperature of 22°C±2°C, and a humidity of 50-60%, with free access to food and water.

[0020] Main reagents:

[0021] Isoflurane: Redwo Life Science Co., Ltd.

[0022] Corn oil: McLean, 8001-30-7

[0023] Dihydrotestosterone: Solebol, ID0310

[0024] Apigenin: MacLean, A823208.

[0025] Establishment of mouse model of androgenic alopecia

[0026] The "2+1" administration mode (i.e., intraperitoneal injection of 50 mg / kg dihydrotestosterone for two consecutive days, followed by another two days of administration after one day) was adopted to simulate the pathological state of human androgenic alopecia.

[0027] Example 1:

[0028] VC group: androgenic alopecia model mice were used as research subjects and 100 μl / 10g of 0.5% CMC-Na solution was given by gavage every day. The hair growth of the mice was recorded by taking photos every other day.

[0029] VC+PC group: androgenic alopecia model mice were used as research subjects. 100μl / 10g minoxidil lotion was applied daily, and photos were taken every other day to record the hair growth of the mice.

[0030] VC+APG group: Androgenic alopecia model mice were used as research subjects and 100 mg / kg APG-0.5% CMC-Na solution was administered orally every day. The hair growth of the mice was recorded by taking photos every other day.

[0031] The results are as follows Figure 1 The results showed that on D3 (Day 3), the skin color of mice in each group was uniform, pink, and the hair cycle was in the resting phase; on D11, the skin color of mice in the PC and APG groups was black, while the skin of mice in the VC group remained in the resting phase. The gross images of mice on D15 and D23 showed that the hair coverage area of ​​mice in the PC and APG groups was significantly larger than that of the other groups during the same period. Dihydrotestosterone treatment caused the hair growth period of mice to be delayed and the growth rate to slow down; while apigenin (APG) intervention can effectively alleviate dihydrotestosterone-induced androgenic alopecia and restore the suppressed hair cycle.

[0032] By observing the hair follicle structure of mice at different stages, we found that Figure 2 ), apigenin can promote androgenic alopecia mice to enter the growth phase earlier and prolong the time that hair follicles stay in the growth phase. In addition, the statistical data collected and measured during the growth and regression phases of hair showed that ( Figure 3 ), the hair growth rate of mice in the APG group was significantly faster than that in the control group. (VC: solvent control group; PC: positive product minoxidil control group; APG: apigenin control group)

[0033] Example 2:

[0034] Experimental subjects were Lgr5-EGFP-creERT2; tdTomato-cko male mice for Lgr5+ hair follicle stem cell lineage tracing. Tamoxifen was injected intraperitoneally at six weeks of age, once every other day for a total of three injections. Hair removal was performed at seven weeks of age. The MC group was modeled using the same method as in Example 1. The APG-treated group was administered daily in addition to the androgen-induced modeling.

[0035] Combine Figure 4 It can be seen that the expression of lgr5+tomato+ cells in hair follicles on D5 and D8 indicates that apigenin promotes the proliferation of lgr5+ hair follicle stem cells. (MC: model control group; APG: 100mg / kg)

[0036] Five days after administration, very few lgr5+tomato+ cells were expressed in the hair follicles of the MC group, indicating that the lgr5+ hair follicle stem cells had not yet proliferated or had only slightly proliferated. Lgr5+tomato+ cells were already expressed in the hair follicles of the LAPG group. Eight days after administration, a small number of lgr5+tomato+ cells were expressed in the hair follicles of the MC group, while the expression of lgr5+tomato+ cells in the hair follicles of the APG group was higher than that in the MC group.

[0037] Finally, it should be noted that the above descriptions are merely preferred embodiments of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art will be able to modify the technical solutions described in the aforementioned embodiments or substitute equivalents for some of the technical features. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. Application of apigenin in the preparation of products for preventing and treating hair loss.

2. The use according to claim 1, characterized in that: The hair loss is a hair loss disease caused by stagnation of the hair growth cycle.

3. The use according to claim 2, characterized in that: The hair loss diseases caused by the stagnation of the hair growth cycle include androgenic alopecia, alopecia areata and anagen effluvium.

4. The use according to claim 1, characterized in that: The product is a medicine or health product that activates the proliferation of hair follicle stem cells, promotes the transition of hair follicles from the resting phase to the growth phase, and promotes hair growth.

5. The use of apigenin in the preparation of a product for preventing and treating hair loss according to claim 4, characterized in that: The medicine or health product is in the form of tablets, capsules, pills or oral liquids.

Images